Vancomycin-resistant enterococcus;Vancomycin-resistente enterokokken

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 43, 2005, Pages 2463-2468

  Dettenkofer, M ^a   Kern, W V ^a   Hübner, Johannes A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RATE; REVIEW; SCREENING TEST; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; UNITED STATES; VANCOMYCIN RESISTANCE;

EID: 27744576602     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-918592     Document Type: Review

References (50)

1. National Nosocomial Infections Surveillance (NNIS). System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31: 481-498
2. Arthur M, Jr. Quintiliani R. Regulation of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob Agents Chemother 2001; 45: 375-381
3. Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol 1996; 4: 401-407
4. Avery R, Kalaycio M, Pohlman B et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 2005; 35: 497-499
5. Baden LR, Thiemke W, Skolnik A et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance". Clin Infect Dis 2001; 33: 1654-1660
6. Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36: 145-158
7. Bonten MJ, Hayden MK, Nathan C et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996; 348: 1615-1619
8. Bonten MJ, Slaughter S, Ambergen AW et al. The role of "colonization pressure" in the spread of vancomycin- resistant enterococci: an important infection control variable. Arch Intern Med 1998; 158: 1127-1132
9. Borneff-Lipp M, Knoll M, Daeschlein G et al. Outbreak of vancomycin-resistant enterococci (VRE) in a hematological oncology ward and hygienic preventive measures. A long-term study. Onkologie 2005; 28: 187-192
10. Christiansen KJ, Tibbett PA, Beresford W et al. Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 2004; 25: 384-390
11. Clewell DB. Bacterial sex pheromone-induced plasmid transfer. Cell 1993; 73: 9-12
12. Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Jr. Moellering RC. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993; 37: 598-601
13. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005; 191: 588-595
14. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta analysis. Clin Infect Dis 2005; 41: 327-333
15. Donskey CJ, Chowdhry TK, Hecker MT et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343: 1925-1932
16. Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000; 37: 57-62
17. Duckro AN, Blom DW, Lyle EA, Weinstein RA, Hayden MK. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch Intern Med 2005; 165: 302-307
18. EARSS. European Antimicrobial Resistance Surveillance System 2005. http://www.earss.rivm.nl/,
19. Fridkin SK, Lawton R, Edwards JR, Tenover FC, Jr. McGowan JE, Gaynes RP. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002; 8: 702-707
20. GENARS. German Network for Antimicrobial Resistance Surveillance. http://www.genars.de/data.htm, 2004
21. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179
22. Hayden MK. Insights into the epidemiology and control of infection with vancomycin- resistant enterococci. Clin Infect Dis 2000; 31: 1058-1065
23. Huenger F, Ruland P, Haefner H et al. Persistent single VRE strain is responsible for two outbreaks in an ICU. Poster auf dem 15. European Congress of Clinical Microbiology and Infectious Diseases, Kopenhagen, 2005
24. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14
25. Kak V, Chow JW. Acquired antibiotic resistance in enterococci. ASM Press, Washington, D.C, M. S. Gilmore (ed.), The enterococci: pathogenesis, molecular biology, and antibiotic resistance. 2002: 355-383
26. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003; 51: 23-30(Suppl 3
27. Kawalec M, Gniadkowski M, Kedzierska J, Skotnicki A, Fiett J, Hryniewicz W. Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype. J Clin Microbiol 2001; 39: 4274-4282
28. Klare I, Witte W. Zum Auftreten und zur Verbreitung glycopeptidresistenter Enterokokken. Epidemiol Bulletin 2005; 17: 149-155
29. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-323
30. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998; 27: 1259-1265
31. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-161
32. May AK, Melton SM, McGwin G, Cross JM, Moser SA, Rue LW. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000; 14: 259-264
33. McGowan JE. Debate-guidelines for control of glycopeptide-resistant enterococci (GRE) have not yet worked. J Hosp Infect 2004; 57: 281-284
34. Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995; 1: 249-253
35. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-142
36. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH Synercid Emergency-Use Study Group. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44: 251-261
37. Moreno F, Jorgensen JH, Weiner MH. An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagn Microbiol Infect Dis 1994; 20: 41-43
38. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-721
39. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002; 23: 429-435
40. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-386
41. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003; 51 Suppl 3: iii13-21
42. PEG. Paul-Ehrlich-Gesellschaft Resistenzdaten http://www.p-e-g.org/ ag_resistenz/main.htm, 2001
43. Raad II, Hanna HA, Hachem RY et al. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother 2004; 48: 3583-3585
44. SARI. Surveillance der Antibiotika-Anwendung und der bakteriellen Resistenzen auf Intensivstationen, http://www.sari-antibiotika.de/allgemei/ funk.htm, 2005
45. Theilacker C, Krueger WA, Kropec A, Huebner J. Rationale for the development of immunotherapy regimens against enterococcal infections. Vaccine 2004; 22: S31-38(Suppl 1
46. Ullmann AJ, Fischer T, Jansen B, Hube C. Early Cessation of a Vancomycin-Resistant Enterococci (VRE) Outbreak in a Hematology-Oncology Department after Implementation of an Enhanced Infection Control Intervention. A Single Center Experience. Poster auf dem 46. AHS Annual Meeting, San Diego, 2004
47. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001; 135: 484-492
48. Weinstein MP, Mirrett S, Kannangara S et al. Multicenter evaluation of use of penicillin and ampicillin as surrogates for in vitro testing of susceptibility of enterococci to imipenem. J Clin Microbiol 2004; 42: 3747-3751
49. Whitman MS, Pitsakis PG, Zausner A et al. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1993; 37: 2069-2073
50. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317